Tango Therapeutics, Inc.

Tango Therapeutics is a clinical-stage precision oncology company focused on discovering and developing novel cancer medicines for patients with defined genetic vulnerabilities and unmet medical needs. Founded in 2017 and headquartered in Boston, Massachusetts, the company leverages the principle of synthetic lethality to create genetically targeted therapies that exploit specific tumor characteristics. Tango Therapeutics' pipeline includes several investigational candidates: TNG462, a methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor in Phase 1/2 clinical trials for pancreatic and lung cancer patients; TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma treatment; and TNG260, a co-repressor inhibitor designed to reverse immune evasion in lung cancer. The company's approach targets defined patient populations with specific genetic mutations, including MTAP-deleted and RAS-mutant cancers. Tango Therapeutics pursues strategic collaborations with major pharmaceutical partners to advance its precision cancer medicine pipeline and expand the reach of genetically targeted therapies in oncology.